



*IFW*

Patent

Atty. Dkt. No. 054707-0661

Application No. 09/835,523

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

Applicant: Yong-Qian Wu et al.

Title: AZA COMPOUNDS, PHARMACEUTICAL COMPOSITIONS AND  
METHODS OF USE

Appl. No.: 09/835,523

Filing Date: 04/17/2001

Examiner: Truong, Tamthom Ngo

Art Unit: 1624

**INFORMATION DISCLOSURE STATEMENT**  
**UNDER 37 CFR §1.56**

Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

Sir:

Submitted herewith on Form PTO/SB/08 is a listing of documents known to Applicants in order to comply with Applicants' duty of disclosure pursuant to 37 CFR §1.56. A copy of each listed document is being submitted to comply with the provisions of 37 CFR §1.97 and §1.98.

The submission of any document herewith, which is not a statutory bar, is not intended as an admission that such document constitutes prior art against the claims of the present application or that such document is considered material to patentability as defined in 37 CFR §1.56(b). Applicants do not waive any rights to take any action which would be appropriate to antedate or otherwise remove as a competent reference any document which is determined to be a *prima facie* art reference against the claims of the present application.

**TIMING OF THE DISCLOSURE**

The listed documents are being submitted in compliance with 37 CFR §1.97(c), before the mailing date of either a final action under 37 CFR §1.113, a notice of allowance under 37 CFR §1.311, or an action that otherwise closes prosecution in the application.

**RELEVANCE OF EACH DOCUMENT**

Any document listed on the attached PTO/SB/08 was cited as being relevant during the prosecution of the corresponding European application. A copy of the European Search Report (EP 00 95 7870, 11 pages) is attached setting forth the portion of each document considered relevant by the examiner.

Applicants respectfully request that any listed document be considered by the Examiner and be made of record in the present application and that an initialed copy of Form PTO/SB/08 be returned in accordance with MPEP §609.

**STATEMENT**

The undersigned hereby states in accordance with 37 CFR §1.97(e)(1) that each item of information contained in this information disclosure statement was first cited in any communication from a foreign patent office in a counterpart foreign application not more than three (3) months prior to filing of this Statement.

The Commissioner is hereby authorized to charge any additional fees which may be required regarding this application under 37 CFR §§ 1.16-1.17, or credit any overpayment, to Deposit Account No. 19-0741. Should no proper payment be enclosed herewith, as by a


Patent  
Atty. Dkt. No. 054707-0661  
Application No. 09/835,523

check being in the wrong amount, unsigned, post-dated, otherwise improper or informal or even entirely missing, the Commissioner is authorized to charge the unpaid amount to Deposit Account No. 19-0741.


Respectfully submitted,

Date June 22, 2004

FOLEY & LARDNER LLP  
Customer Number: 29728  
Telephone: (202) 295-4166  
Facsimile: (202) 672-5399

By  (45,943)  
SEAN A. PASSARO FOR  
Suet M. Chong  
Attorney for Applicant  
Registration No. 38,104

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

 Substitute for form 1449B/PTO <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b> (use as many sheets as necessary)		<b>Complete if Known</b>	
		Application Number	09/835,523
Filing Date		04/17/2001	
First Named Inventor		Yong-Qian Wu	
Group Art Unit		1624	
Examiner Name		Truong, Tamthom Ngo	
Attorney Docket Number		054707-0661	
Sheet	of 2		

U.S. PATENT DOCUMENTS						
Examiner Initials*	Cite No. <sup>1</sup>	U.S. Patent Document		Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number	Kind Code <sup>2</sup> (if known)			
	A1	4,801,706		WINKLEY et al.	01/31/1989	
	A2	5,399,565		GREENWOOD et al.	03/21/1995	
	A3	5,670,503		KAWAI et al.	09/23/1997	
	A4	5,798,355		STEINER et al.	08/25/1998	

FOREIGN PATENT DOCUMENTS								
Examiner Initials*	Cite No. <sup>1</sup>	Foreign Patent Document			Name of Patentee or Applicant of Cited Documents	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T <sup>6</sup>
		Office <sup>3</sup>	Number <sup>4</sup>	Kind Code <sup>5</sup> (if known)				
	A5	CA	2,271,837	A1	ARZNEIMITTEL WERK DRESDEN GMBH, DE	11/11/1999		
	A6	EP	0 104 484	A1	NIPPON KAYAKU KABUSHIKI KAISHA	04/04/1984		
	A7	EP	0 450 757	A2	GLAXO GROUP LIMITED	10/09/1991		
	A8	EP	0 778 023	A1	AMERICAN HOME PRODUCTS CORPORATION	06/11/1997		
	A9	WO	89/06535	A1	E.R. SQUIBB & SONS, INC.	07/27/1989		
	A10	WO	94/19350	A1	FUJISAWA PHARMACEUTICAL CO., LTD.	09/01/1994		
	A11	WO	99/20272	A1	MERCK & CO., INC.	04/29/1999		
	A12	WO	96/05180	A1	ABBOTT LABORATORIES	02/22/1996		
	A13	WO	99/46248	A1	VERTEX PHARMACEUTICALS INCORPORATED	09/16/1999		
	A14	WO	98/05333	A1	MOLECUMETICS LTD	02/12/1998		

NON PATENT LITERATURE DOCUMENTS					
Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published.			T <sup>6</sup>
	A15	BALDWIN et al., "Pyrazolotriazines: a new class of tumour-inhibitory agents," J. Pharm. Vol. 18, pp. 1S-4S (May 2, 1966).			
	A16	Borloo et al., "Synthesis and evaluation of azaprolin peptides as potential inhibitors of dipeptidyl peptidase IV and prolyl oligopeptidase," Letters in Peptide Science, vol. 2, pp. 198-202 (1995).			

Examiner Signature	Date Considered
--------------------	-----------------


\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Unique citation designation number. <sup>2</sup> See attached Kinds of U.S. Patent Documents. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document.

<sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup> Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

 Substitute for form 1449B/PTO <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b> (use as many sheets as necessary)		<b>Complete if Known</b>	
		Application Number	09/835,523
		Filing Date	04/17/2001
		First Named Inventor	Yong-Qian Wu
		Group Art Unit	1624
		Examiner Name	Truong, Tamthom Ngo
Sheet	2	of	2
		Attorney Docket Number	054707-0661

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>6</sup>
	A17	STEINER et al., "Neurotrophic actions of nonimmunosuppressive analogues of immunosuppressive drugs FK506, rapamycin and cyclosporin A," Nature Medicine, vol. 3, no. 4, pp. 421-428 (April 1997).	

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Unique citation designation number. <sup>2</sup> See attached Kinds of U.S. Patent Documents. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document.

<sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup> Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.